Asthma treatment

61. AFX UK Focus – April 30, 2008 AFX UK (Focus): Glaxo: FDA OKs Advair 250/50 to reduce exacerbations in COPD patients SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline late Wednesday said the Food and Drug Administration has approved its Advair Diskus 250/50 for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. With this approval, Advair becomes the only treatment the FDA has approved to reduce COPD exacerbations and improve lung function, Glaxo said. Advair …. AFX Europe Focus – April 30, 2008 AFX Europe (Focus): Glaxo: FDA OKs Advair 250/50 to reduce exacerbations in COPD patients SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline late Wednesday said the Food and Drug Administration has approved its Advair Diskus 250/50 for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. With this approval, Advair becomes the only treatment the FDA has approved to reduce COPD exacerbations and improve lung function, Glaxo said. Advair …. AFX Asia Focus – April 30, 2008 AFX Asia (Focus): Glaxo: FDA OKs Advair 250/50 to reduce exacerbations in COPD patients SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline late Wednesday said the Food and Drug Administration has approved its Advair Diskus 250/50 for the reduction of exacerbations in patients with chronic obstructive pulmonary disease. COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. With this approval, Advair becomes the only treatment the FDA has approved to reduce COPD exacerbations and improve lung function, Glaxo said. Advair …. THE ORLANDO SENTINEL – November 26, 1999 NEW ASTHMA TREATMENT PACKS 1-2 PUNCH: 1 INHALER, 2 DRUGS AN FDA COMMITTEE HAS RECOMMENDED APPROVAL OF ADVAIR, SAYING IT’S RELATIVELY EASY TO USE. WASHINGTON – An asthma medicine that doctors hope will make it easier for patients to adhere to their therapy took a step toward the market this week as government advisers recommended approval of Advair. Advair is not a new drug. It merely combines into one inhaler device two existing asthma treatments – the long-acting inhaled bronchodilator Serevent, which helps keep airways open, and the inhaled corticosteroid Flovent, which fights inflammation. Manufacturer Glaxo Wellcome estimates ….. (PA) – November 19, 2005 FDA: Beef up Advair warning, The asthma drug may aggravate episodes, the agency said. Its producer, GlaxoSmithKline, disagreed with the finding. Regulators told GlaxoSmithKline P. L. C. yesterday to add stricter risk warnings to its top-selling asthma drug Advair, sending Glaxo shares lower and drawing a challenge from the company. The U. S. Food and Drug Administration’s Safety Information and Adverse Event Reporting Program said use of Advair Diskus and Serevent Diskus may increase the chance of severe asthma episodes, which sometimes can be fatal. The FDA also singled out Foradil Aerolizer, made by Novartis AG. It ….. Datamonitor – June 27, 2007 AstraZeneca: Symbicort to compete with Advair, AstraZeneca’s Symbicort will be the second combination treatment for asthma to enter US market After several delays, AstraZeneca’s Symbicort asthma inhaler has been launched in the US, making it the second ICS/LABA combination available in this market. However, its late entry and lack of approval for the SMART indication means it will face tough competition from GlaxoSmithKline’s Advair which currently dominates the respiratory market. AstraZeneca’s Symbicort (budesonide/formoterol) pressurized metered dose inhaler has been launched in the ….. AFX Europe Focus – April 18, 2007 AFX Europe (Focus): Glaxo gets marketing OK for Advair and Arixtra in Japan LONDON (Thomson Financial) – Europe’s biggest drug maker GlaxoSmithKline PLC has received marketing approval in Japan for its asthma treatment Seretide/Advair, and Arixtra, an injection to prevent blood clots. Seretide/Advair will be branded Advair Diskus, and has been approved for adult patients with bronchial asthma. Glaxo said it will be the only combination respiratory medicine available in Japan. David Stout, president of pharmaceuticals, said the company expects sales …. AFX UK Focus – April 18, 2007 AFX UK (Focus): Glaxo gets marketing OK for Advair and Arixtra in Japan LONDON (Thomson Financial) – Europe’s biggest drug maker GlaxoSmithKline PLC has received marketing approval in Japan for its asthma treatment Seretide/Advair, and Arixtra, an injection to prevent blood clots. Seretide/Advair will be branded Advair Diskus, and has been approved for adult patients with bronchial asthma. Glaxo said it will be the only combination respiratory medicine available in Japan. David Stout, president of pharmaceuticals, said the company expects sales …. AFX Europe Focus – May 21, 2008 AFX Europe (Focus): GlaxoSmithKline: No increase in cardiac events in patients treated with Advair SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline said Wednesday that a three-year study of chronic obstructive pulmonary disease found that patients being treated with Advair Diskus 500/50 experienced the fewest adverse cardiac events compared with patients taking other treatments or a placebo. The data was part of the TOwards a Revolution in COPD Health study of 6, 000 patients that was presented at the International Conference of the American Thoracic Society meeting in Toronto ….. AFX UK Focus – May 21, 2008 AFX UK (Focus): GlaxoSmithKline: No increase in cardiac events in patients treated with Advair SAN FRANCISCO (Thomson Financial) – GlaxoSmithKline said Wednesday that a three-year study of chronic obstructive pulmonary disease found that patients being treated with Advair Diskus 500/50 experienced the fewest adverse cardiac events compared with patients taking other treatments or a placebo. The data was part of the TOwards a Revolution in COPD Health study of 6, 000 patients that was presented at the International Conference of the American Thoracic Society meeting in Toronto ….